An omega-3 label can contain several numbers that look as though they describe the same thing.
They do not.
A capsule might list the weight of fish oil, the amount of total omega-3 fatty acids, and separate quantities for EPA and DHA.
Those fields need to be normalized before two products can be compared meaningfully.
Bextera ingredient specification
Omega-3 Fatty Acids
ALA, EPA and DHA
Most clinical research focuses on ALA, EPA and DHA. ALA is essential, but its conversion into EPA and DHA is limited, making direct EPA and DHA quantities important product-comparison fields.
EPA per serving, DHA per serving, combined EPA+DHA, source oil, serving size, cost per gram EPA+DHA and independent testing evidence
Do not compare total oil with active omega-3 content
These values describe nutrition reference points and research contexts, not individualized supplement recommendations.
| Protocol | Amount | Duration | Context |
|---|---|---|---|
| Adult ALA adequate intake — men | 1.6 g/day | Daily AI | Adequate Intake applies to ALA, not EPA+DHA |
| Adult ALA adequate intake — women | 1.1 g/day | Daily AI | Adequate Intake applies to ALA, not EPA+DHA |
| Prescription omega-3 context | 4 g/day | Clinical treatment context | Prescription EPA or EPA+DHA has been used to lower high triglycerides; this is not equivalent to a general OTC supplement recommendation |
Where the signal is strongest
ALA conversion
ALA can be converted into EPA and then DHA, but conversion is limited. Direct dietary or supplemental EPA and DHA therefore cannot be inferred from the ALA amount.
Triglycerides
Long-chain omega-3 intake lowers serum triglyceride levels, with effects generally larger at higher intake and in people with higher baseline triglycerides.
Cardiovascular outcomes
Cardiovascular trial results are not uniform. Findings differ by formulation, dose, population and outcome, so triglyceride reduction should not be treated as proof of identical effects on every cardiovascular endpoint.
Food vs supplement evidence
Evidence supporting fish and seafood intake as part of a healthful dietary pattern is not identical to evidence for omega-3 supplement capsules.
What the evidence requires us to qualify
- No tolerable upper intake level has been established for omega-3 fatty acids.
- FDA has concluded that supplements providing no more than 5 g/day of EPA plus DHA are safe when used as recommended; this is a safety boundary, not a recommended intake target.
- Two large trials using 4 g/day omega-3 formulations for several years found a small increase in atrial-fibrillation risk among people with cardiovascular disease or high cardiovascular risk.
- High-dose fish oil can have antiplatelet effects, so anticoagulant use belongs in the safety context.
- Common supplement side effects are generally mild and can include gastrointestinal discomfort, nausea, heartburn and unpleasant taste.
Fish oil is not the same number as EPA plus DHA
Consider a hypothetical capsule containing 1,000 mg of fish oil.
That does not mean it contains 1,000 mg of EPA and DHA.
The oil contains a mixture of fatty acids and other components. The Supplement Facts panel should therefore be read for the actual EPA and DHA quantities rather than treating total oil weight as the active omega-3 dose.
For Bextera, these become separate database fields:
- total oil per serving;
- total omega-3s;
- EPA;
- DHA;
- other declared omega-3s.
That prevents a physically larger capsule from automatically looking like the higher-specification product.
ALA, EPA and DHA should not be collapsed into one field
The three omega-3 fatty acids receiving most scientific attention are alpha-linolenic acid, EPA and DHA.
ALA is an essential fatty acid, meaning the body needs to obtain it from the diet.
The body can convert ALA into EPA and subsequently DHA, but NIH describes that conversion as very limited.
This matters when comparing plant-based and marine omega-3 products.
A product containing a large amount of ALA should not simply be converted on paper into an equivalent EPA+DHA dose.
EPA and DHA deserve their own columns
EPA and DHA often appear together in supplement marketing, but a useful specification table keeps them separate.
That allows Bextera to calculate:
- EPA per serving;
- DHA per serving;
- combined EPA+DHA;
- cost per gram of EPA+DHA;
- EPA-to-DHA ratio.
Those numbers are considerably more informative than bottle size or the words “high strength fish oil.”
Source oil is another independent variable
EPA and DHA can come from several sources.
Fish oil is common, while algal oil provides a non-fish source and is ultimately connected to the microalgae from which marine food chains obtain these fatty acids.
Krill oil is another marine source.
Cod liver oil differs again because it can also contain meaningful amounts of vitamins A and D.
That means source belongs in the specification database, but source alone should not determine the product ranking.
The useful question remains: what fatty acids does the serving actually deliver?
There is no general EPA+DHA RDA
This is another area where supplement pages often oversimplify the evidence.
For people age one and older, U.S. Adequate Intake values for omega-3 fatty acids apply specifically to ALA.
There is no established Recommended Dietary Allowance for EPA or DHA.
For adults, the Adequate Intake for ALA is 1.6 grams per day for men and 1.1 grams per day for women.
Those values should not be presented as EPA+DHA recommendations.
Triglyceride lowering is one of the clearer clinical signals
Long-chain omega-3 fatty acids have been studied extensively in relation to blood lipids.
The evidence consistently shows a triglyceride-lowering effect.
NIH summarizes a Cochrane review covering 86 randomized controlled trials in which long-chain omega-3 supplementation reduced triglyceride levels by about 15% on average.
That does not mean every over-the-counter fish-oil capsule is a treatment for high triglycerides.
Prescription omega-3 products using substantially higher controlled doses are a different regulatory and clinical context.
The American Heart Association has concluded that 4 grams per day of prescription omega-3 fatty acids can lower elevated triglyceride levels.
Bextera will keep prescription therapeutic evidence separate from consumer supplement specifications.
Triglycerides and cardiovascular events are different outcomes
A product can affect a blood marker without producing the same effect on every clinical outcome.
This distinction is particularly important for omega-3 supplements.
Large cardiovascular trials have produced different results depending on formulation, study population, dose, background therapies and the endpoint being measured.
For example, trials using different 4-gram omega-3 formulations have not produced identical cardiovascular-event results.
That makes a blanket statement such as “omega-3 prevents heart disease” much less defensible than explaining the individual outcome being studied.
Food evidence is not identical to capsule evidence
Fish and seafood consumption is consistently associated with healthful dietary patterns.
But eating fish changes more than omega-3 intake.
Fish can replace other foods in the diet and supplies protein, micronutrients and other components.
A capsule does not recreate that entire dietary substitution.
Bextera therefore keeps evidence about fish consumption separate from evidence about isolated omega-3 supplements.
Higher doses require additional safety context
Omega-3 supplements are generally well tolerated, but higher-dose research requires more nuance.
NIH notes that FDA considers supplements providing up to approximately 5 grams per day of EPA plus DHA safe when used as recommended.
That figure is a safety assessment, not a target intake.
Two large clinical trials using 4 grams per day for several years also reported a small increase in atrial fibrillation among participants with cardiovascular disease or elevated cardiovascular risk.
That is precisely why Bextera will not convert “more EPA+DHA per dollar” into an automatic quality score.
Anticoagulant use belongs in the safety discussion
Fish oil can have antiplatelet effects at high doses.
Research has not generally shown clinically significant bleeding at typical studied doses, but interaction context matters for people taking anticoagulants such as warfarin.
This is another example of information that belongs in a specification dossier but should not be reduced to a red or green product badge.
Our product comparison should answer nine questions
For omega-3 products, Bextera will record:
- What is the source oil?
- How much total oil is supplied?
- How much EPA is supplied?
- How much DHA is supplied?
- What is the combined EPA+DHA amount?
- Are other omega-3 fatty acids declared?
- What does one gram of EPA+DHA cost?
- Are oxidation, purity or contaminant-testing claims independently verifiable?
- Does the product contain other meaningful active nutrients?
That gives us a much more useful comparison than simply ranking bottles by the largest milligram number.
What Bextera will not equate
We will not treat:
1,000 mg fish oil
as the same thing as:
1,000 mg EPA+DHA.
We will not treat ALA as automatically equivalent to EPA+DHA.
We will not convert prescription omega-3 evidence into an over-the-counter product claim.
And we will not treat a triglyceride reduction as proof that every cardiovascular outcome changes in the same direction.
Those distinctions are the reason the specification layer exists.
Sources & evidence
Research used for this dossier
- Omega-3 Fatty Acids — Health Professional Fact Sheet
NIH Office of Dietary Supplements